Skip to content

Inspection Record

RayzeBio, Inc — FDA 483 Findings

US FDAInspected 2026-02-24Published 2026-10-20 11 findingsDocumentation and recordsAseptic processing and sterility assuranceTraining and personnelDeviation, CAPA, and investigationMaterial and supplier controlQuality unit oversightLaboratory and QC controlsEquipment and facility

Inspectors Muna Algharibeh · Scott McGrewThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Documentation and records

Master production and control records lack a statement of theoretical yield including the maximum and minimum percentages of theoretical yield beyond which investigation is required.

2Aseptic processing and sterility assurance

Equipment are not cleaned, maintained, sanitized or sterilized at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product.

3Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.

4Training and personnel

Employees engaged in the manufacture, processing, packing and holding of a drug product lack the training required to perform their assigned functions.

5Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet to any of its specifications Specifically, A.

6Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

7Aseptic processing and sterility assurance

Your firm failed to provide adequate system for cleaning and disinfecting the room and equipment to produce aseptic condition.

8Material and supplier control

Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.

9Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

10Laboratory and QC controls

Laboratory records do not include complete records of any testing and standardization of laboratory reference standards.

11Equipment and facility

Routine calibration of automatic and electronic equipment is not performed according to a written program designed to assure proper performance.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

RayzeBio, Inc findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.